| Literature DB >> 30546561 |
Naofumi Yoshida1, Noritoshi Hiranuma1, Taira Ninomaru1, Yuichi Nagamatsu1, Naoki Tamada1, Tatsuya Miyoshi1, Yoshihiro Sasaki1, Gaku Kanda1, Noriyasu Kobayashi1, Takashi Fujii1.
Abstract
Essential thrombocythemia (ET) has been reported to cause acute coronary disease. However, the efficacy of anti-platelet therapy for ET is unclear since there are individual differences in the platelet function of ET patients. Here we report a case of a 62-year-old man with ET who was admitted to our hospital because of acute coronary syndrome. He underwent coronary angioplasty. Dual anti-platelet therapy with aspirin (81 mg/day) and clopidogrel (75 mg/day) was subsequently initiated. We evaluated platelet reactivity in P2Y12 reaction units, and subsequently determined anti-platelet drugs and corresponding doses. <Learning objective: Essential thrombocythemia (ET) is a myeloproliferative disorder that causes acute coronary disease. As there are individual differences in the platelet function of patients with ET, the efficacy of anti-platelet therapy for these patients varies. Evaluation of platelet reactivity using P2Y12 reaction units is useful in determining appropriate anti-platelet drugs and corresponding doses.>.Entities:
Keywords: Acute coronary syndrome; Dual anti-platelet therapy; Essential thrombocythemia; P2Y12 reaction unit
Year: 2015 PMID： 30546561 PMCID： PMC6281974 DOI： 10.1016/j.jccase.2015.03.007
Source DB: PubMed Journal: J Cardiol Cases ISSN： 1878-5409